Toxoplasma IgM antibodies indicate a recent or acute infection with Toxoplasma gondii, since IgM is the first antibody produced. However, IgM can persist for months or give false positives, so a single positive result doesn’t always mean very recent infection. Confirmatory testing (IgG, IgG avidity or repeat tests) and clinical correlation are important, especially during pregnancy.

IgM antibody positive indicates a recent or current infection. IgM is the first antibody the body makes after exposure, usually appearing within days to a few weeks. A positive IgM suggests an acute or early-phase immune response, but may be transient or false-positive. Clinicians often confirm with repeat testing, IgG measurement, or direct tests (for example, PCR) to clarify timing and status.

A toxoplasmosis IgM negative result generally means there is no recent (acute) infection. If IgG is positive and IgM negative, it usually indicates past infection and likely immunity. If both IgG and IgM are negative, you are susceptible to new infection. False negatives can occur early after exposure, so if pregnancy, symptoms, or recent exposure are concerns, repeat testing or IgG/avidity testing is advised.

Most laboratories report Toxoplasma IgM as an index or IU/mL. Typical cutoffs: negative (normal) <0.9–1.0, equivocal ~0.9–1.1, and positive >1.1, though exact thresholds vary by assay. Interpret results alongside laboratory-specific reference ranges and clinical context; confirmatory testing (IgG and avidity) is often needed to determine recent infection. Discuss results with your clinician.

Toxoplasma IgM usually appears within 1–2 weeks of infection and commonly remains detectable for about 6–18 months. In many people levels fall by 3–12 months, but IgM can persist longer (occasionally up to 2 years or more), causing possible misinterpretation of recent infection. Repeat testing and IgG avidity testing help distinguish recent from past infection.

Toxoplasma gondii cannot be fully eradicated once tissue cysts form. Antiparasitic regimens (commonly pyrimethamine plus sulfadiazine with folinic acid, or alternatives) treat acute or severe infections and protect fetus or immunocompromised people; some patients need long-term maintenance. Healthy, immunocompetent individuals often have mild, self-limited illness. Treatment controls active disease but does not reliably eliminate latent cysts.